Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Robust generation of honemogeneous midbrain organoids with in vivo–like cellular composition facilitates neurotoxin-based Parkinson’s disease modeling

ABSTRACT: Robust generation of honemogeneous midbrain organoids with in vivo–like cellular composition facilitates neurotoxin-based Parkinson’s disease modeling

PROVIDER: PRJNA506225 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8208880_1.fastq.gz	Fastqsanger.gz
	SRR8208880_2.fastq.gz	Fastqsanger.gz
	SRR8208881_1.fastq.gz	Fastqsanger.gz
	SRR8208881_2.fastq.gz	Fastqsanger.gz
	SRR8208882_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

Modelling G2019S-LRRK2 sporadic Parkinson’s disease in 3D midbrain organoids

Project description:Recent advances in generating 3 dimensional (3D) organoid systems from stem cells offer new possibilities for disease modeling. In this study, we generate isogenic 3D midbrain organoids with or without a Parkinson’s disease-associated LRRK2 G2019S mutation. LRRK2-G2019S midbrain organoids derived from LRRK2 targeted human iPSCs in vitro have LRRK2-associated sporadic Parkinson's disease phenotypes. Midbrain-like 3D organoids expressing LRRK2-G2019S showed dynamic changes in globle gene expression.

2019-02-02 | GSE125234 | GEO

Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids [scRNA-Seq]

Project description:Parkinson’s disease, an aging-associated neurodegenerative disorder, is characterised by nigrostriatal pathway dysfunction caused by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain. Human in vitro models are enabling the study of the dopaminergic neurons’ loss, but not the dysregulation within the dopaminergic network in the nigrostriatal pathway. Additionally, these models do not incorporate aging characteristics which potentially contribute to the development of Parkinson’s disease. Here we present a nigrostriatal pathway model based on midbrain-striatum assembloids with inducible aging. We show that these assembloids can develop characteristics of the nigrostriatal connectivity, with catecholamine release from the midbrain to the striatum and synapse formation between midbrain and striatal neurons. Moreover, Progerin-overexpressing assembloids acquire aging traits that lead to early neurodegenerative phenotypes. This model shall help to reveal the contribution of aging as well as nigrostriatal connectivity to the onset and progression of Parkinson’s disease.

2023-10-28 | GSE241631 | GEO

Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids [RNA-Seq]

2023-10-28 | GSE236458 | GEO

Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids

Project description:Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids

| PRJNA1009011 | ENA

Robust generation of honemogeneous midbrain organoids with in vivo–like cellular composition facilitates neurotoxin-based Parkinson’s disease modeling

Project description:We could establish the advanced protocol for generating homogeneous and mature midbrain organoids by manipulating SMAD inhibitor combination and in vitro WNT gradient elaborately.

2018-11-21 | GSE122729 | GEO

Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids [RNA-Seq]

Project description:Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids [RNA-Seq]

| PRJNA991423 | ENA

Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids [scRNA-Seq]

Project description:Modeling early phenotypes of Parkinson’s disease by age-induced midbrain-striatum assembloids [scRNA-Seq]

| PRJNA1009018 | ENA

Modeling PD in midbrain-like organoids

Project description:Modeling PD in midbrain-like organoids

| PRJNA525884 | ENA

Production of highly uniform midbrain organoids from human pluripotent stem cells

Project description:Brain organoids have been considered as an advanced platform for in vitro disease modeling and drug screening, but numerous roadblocks exist, such as lack of large-scale production technology and lengthy protocols with multiple manipulation steps, impeding the industrial translation of brain organoid technology. Here we describe the high-speed and large-scale production of midbrain organoids using a high-throughput screening-compatible platform within 30 days. Micro midbrain organoids (µMOs) exhibit a highly uniform morphology and gene expression pattern with minimal variability. Notably, µMOs show dramatically accelerated maturation, resulting in the generation of functional µMOs within only 30 days of differentiation. Furthermore, individual µMOs display highly consistent responsiveness to neurotoxin, suggesting their usefulness as an in vitro high-throughput drug toxicity screening platform. Collectively, our data indicates that µMO technology could represent an advanced and robust platform for in vitro disease modeling and drug screening for human neuronal diseases.

2023-07-28 | GSE236375 | GEO

Single cell atlas of the human midbrain reveals cell state specific to Parkinson’s disease

Project description:Using single-nucleus RNA sequencing, we profiled postmortem midbrain tissue from Idiopathic Parkinson’s Disease patients and matched controls.

2020-09-17 | GSE157783 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data